The coronavirus disease 2019 (COVID-19) pandemic has significantly disrupted the provision of non-COVID-19–related medical care (1). This may disparately impact patients with type 2 diabetes, as prolonged disruptions to physician services and regular hemoglobin A1c (HbA1c) testing could negatively impact glycemic control and increase the probability of acute complications (2). While recent research finds no observable changes in medication fill rates or HbA1c levels (3), evidence of how pandemic-induced disruptions impact health outcomes remains limited. In this study, we leveraged electronic health record data from Epic’s Cosmos research platform to identify a large, geographically diverse cohort of adults (aged ≥18 years) with type 2 diabetes and examined changes in utilization of diabetes-related outpatient services and acute care for diabetes-related complications during the pandemic.
Patiëntvoorbeelden m.b.t. vergoeding
- ten laste van verzekeraar
- geen vergoeding door verzekeraar